🚨 New blog series on liquid biopsy ahead of #JPM24: I examine GRAIL's divestment, valuation, why it is in danger despite nearly $3B in funding and its potential impact on liquid biopsy field. Your views are welcome linkedin.com/pulse/grail-di… #Liquidbiopsy #GRAIL #cancer

Excited to join #JPM24 in San Francisco, presenting Mursla Bio Bio's innovative work. We're discussing AI-enhanced liver cancer tests and breakthroughs in Extracellular Vesicles. Our focus: integrating EV multi-omics and AI for advanced healthcare solutions. Grateful for this

🚨 New blog series on liquid biopsy back from #JPM24: I provide my final comments on GRAIL's divestment, why there is almost no buyer, how to address that and lessons for the field. Your views are welcome linkedin.com/pulse/grail-di… #Liquidbiopsy #GRAIL #cancer #screening

New work from the lab describing a mechanism whereby liver extracellular vesicles signal to pancreas and muscle via endocrine signalling to restore euglycaemia in the postprandial state #diabetes Nature Metabolism Paula Miotto nature.com/articles/s4225… nature.com/articles/s4225…

🚨Extracellular Vesicles (EVs) & Liquid Biopsy Evolution 🚀 #MISEV2023 marks an important moment in EV research. Proud to be a co-author for Mursla Bio Bio! 💡Discover how #MISEV2023 is setting new standards in EV analysis & phenotyping, advancing cancer detection & personalised

🌟 NEW PAPER ALERT: Breakthrough liquid biopsy publication in Cell🌟 Excited to share that our liquid biopsy tech is featured in iScience! 🎉 Our paper, "An electro-optical platform for ultrasensitive detection of small extracellular vesicle sub-types," showcases our

🚀 Mursla Bio Expands to the US with New Office in Cambridge, MA! 🚀 We are thrilled to announce our expansion into the US market with a new office in Cambridge, Massachusetts! This marks a major step in transforming cancer diagnosis and treatment through our novel liquid biopsy

𝐓𝐡𝐞 𝐋𝐢𝐯𝐞𝐫 𝐌𝐞𝐞𝐭𝐢𝐧𝐠: Mursla Bio presented data suggesting that its EvoLiver diagnostic test can spot liver cancer among cirrhotic patients with 86% early-stage sensitivity and 88% specificity. #TLM24 Full video: biotechtv.com/post/mursla-bi…

BioCentury's latest Emerging Company Profile features Mursla Bio, which is using extracellular vesicles to detect cancer. Led by ex-banker Pierre Arsène, the company's first goal is surveillance of cirrhosis patients at risk of liver cancer buff.ly/3PDLQ78

🎉 We are thrilled to share that Mursla Bio has been shortlisted for TWO awards at the 2025 Cambridge Independent (Cambridge Independent) Science and Technology Awards – The Award for Innovation and MedTech Company of the Year! Being recognised in Cambridge—one of the most vibrant and

We are proud to announce that EvoLiver™, Mursla Bio’s flagship test for liver cancer surveillance, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). The FDA awards Breakthrough Device Designation to a select number of medical

🧠 Introducing the Mursla Bio AI Precision Medicine Platform Mursla Bio is proud to announce the launch of its AI Precision Medicine Platform, a full-stack solution enabling organ-specific, multi-omic analysis from blood to advance precision diagnostics and patient

Extracellular Vesicle Diagnostic Platform Launched by Mursla Bio Mursla Bio uses #extracellularvesicle data to diagnose and monitor #livercancer more precisely than other available methods Pierre Arsène #AI hubs.li/Q03svDHx0

🧬 Mursla Bio was recently featured in a new article by STAT , as a leading company that’s supporting the shift to extracellular vesicles (EVs) for early cancer detection. The article explains why many experts are looking beyond DNA-based blood tests. DNA is often present

✨ We are pleased that Mursla Bio’s core technology was recently featured on Revvity (NYSE: RVTY) website, highlighting its unique precision diagnostic capabilities. The article discusses how Mursla’s approach to isolating organ-specific extracellular vesicles (EVs) from